Lilly obesity drug shows promising results in teenagers in new study

INDIANAPOLIS, Ind. (WOWO) — A weight-loss drug made by Indianapolis-based Eli Lilly is showing promising results in teenagers, potentially expanding treatment options for younger patients with obesity.

A new clinical trial found that adolescents taking tirzepatide, the active ingredient in Lilly’s Zepbound, experienced an average 18.5% reduction in body mass index after 72 weeks of treatment.

The study, published Sunday in the Journal of the American Medical Association and presented at ObesityWeek, involved 160 participants between the ages of 12 and 17 who had obesity or were overweight with at least one obesity-related health condition…

Story continues

TRENDING NOW

LATEST LOCAL NEWS